Open trial of nefazodone for combat veterans with posttraumatic stress disorder.
Fourteen combat veterans completed a 9-week open trial of nefazodone for treatment of posttraumatic stress disorder (PTSD). Overall PTSD symptoms as measured by the Clinician-Administered PTSD Scale (CAPS) showed a modest but statistically significant decrease with nefazodone treatment. Decreases in CAPS reexperiencing and avoidance, but not hyperarousal symptoms, approached statistical significance. Anxiety decreased significantly, and there were trends toward decreased depression and anger on structured assessments. This study adds to the clinical evidence that nefazodone may be helpful for the management of PTSD symptoms.
Garfield
D A
DA
Department of Psychiatry and Behavioral Sciences, Finch University of Health Sciences/The Chicago Medical School, North Chicago, Illinois 60064, USA. fichtnec@mis.finchcms.edu
Fichtner
C G
CG
Leveroni
C
C
Mahableshwarkar
A
A
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D003130:Combat Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines; D011569:Psychiatric Status Rating Scales; D013313:Stress Disorders, Post-Traumatic / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011795:Surveys and Questionnaires; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014728:Veterans / Q000523:psychology*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone